Skip to main content
. 2020 Jul 20;21(14):5137. doi: 10.3390/ijms21145137

Figure 3.

Figure 3

Figure 3

Changes in Janus kinase (JAK)-signal transducers and activators of transcription protein (STAT) pathway-related molecules after treatment with ruxolitinib. Western blotting showed changes in the levels of phosphorylated (A) JAK1, (B) JAK2, and (C) JAK3, (D) STAT1, (E) STAT3, and (F) STAT5, and (G) DKK1, (H) β-catenin, and (I) GSK-3β. The bands indicate serial protein expression levels up to 2 h after ruxolitinib treatment. The data represent the means ± SEM, n = 4, statistically significant at * p < 0.05, ** p < 0.01, *** p < 0.001 compared to control and # p < 0.05 compared with the IFN-γ-2 h treated group.